Medeze advances ATMP hub role with FDA license, partnerships, and expansion
Thai FDA drug manufacturing license and ATMP Sandbox Medeze obtained a modern drug manufacturing license from the Thai FDA and became the first in Thailand to meet Cell Bank standards, joining the ATMP Regulatory Sandbox. This regulatory progress strengthens its leadership and opens doors to advanced therapies, supporting future revenue growth.
This is a key regulatory milestone that directly enhances Medeze's competitive position and future business prospects.
Partnership with Bangkok Hospital Udon Medeze signed an MOU with Bangkok Hospital Udon to offer stem cell storage, immune testing, and anti-aging services. This expands its customer base and demand for its services, likely boosting revenue and market presence.
This partnership directly increases demand for Medeze's services and expands its reach.
Second-half recovery and expansion plans Medeze expects Q3 2026 results to recover, with GMP approval expected by Q4 2026, clinical trials for knee osteoarthritis and skin rejuvenation starting soon, and Philippine expansion via franchise. These initiatives signal growth and product pipeline progress.
This provides concrete updates on operational recovery and future growth drivers.
GMDP certification for cell therapy production Medeze received GMDP PIC/S certification from the Thai FDA, allowing production for Phase 1-2 human trials of mesenchymal stem cells. This regulatory approval validates its manufacturing quality and supports future commercial cell therapies.
This certification is a critical step toward commercializing advanced therapies, enhancing long-term growth potential.